Filtered By:
Condition: Asthma
Drug: Xolair
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1038 results found since Jan 2013.
Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study
The objective of this study is to evaluate the effect of omalizumab as an adjunct to endoscopic sinus surgery (ESS) on the treatment of CRSwNP under real-life conditions.Recent FindingsSince the introduction of omalizumab, as the first biologic agent for the treatment of diseases such as severe allergic asthma, different studies have demonstrated an effect of omalizumab on CRSwNP, with significant improvements in sinonasal symptoms and endoscopic scores. The high efficacy derived from mAb therapy and the need for ESS prior to mAb recommended by guidelines, has led to compare both therapeutic alternatives, finding discrepan...
Source: Current Allergy and Asthma Reports - September 19, 2023 Category: Allergy & Immunology Source Type: research
Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
While both the AAAAI/ACAAI and the EAACI/GA2LEN/EuroGuiDerm/APAAACI guidelines recommend starting cyclosporine for patients with chronic urticaria who have had an inadequate response to omalizumab, many clinician...
Source: Allergy, Asthma and Clinical Immunology - August 29, 2023 Category: Allergy & Immunology Authors: Anthony F. LaCava and Olajumoke O. Fadugba Tags: Case report Source Type: research
Retrospective Analysis and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma
Monoclonal antibodies (MAbs), including omalizumab, mepolizumab, benralizumab and dupilumab revolutionized severe asthma therapy. Each MAb is effective, none clearly superior.1 –3 Nonetheless, many patients switch MAbs due to insufficient response, side effects or to treat comorbidities. Switching MAbs often improves asthma, yet the frequency, causality and outcome of switches remain understudied.4–6 Thus, universal, standardized responder criteria are needed. “Biolo gics Asthma Response Score” (BARS) combines asthma control test, daily oral corticosteroid dose and annualized exacerbation rate, using a scoring syst...
Source: Annals of Allergy, Asthma and Immunology - August 12, 2023 Category: Allergy & Immunology Authors: Moritz Z. Kayser, Ben L. J ülicher, Tobias Welte, Jan Fuge, Hendrik Suhling Tags: Letters Source Type: research
Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma
Monoclonal antibodies (MAbs), including omalizumab, mepolizumab, benralizumab, and dupilumab, revolutionized severe asthma therapy. Each MAb is effective, none clearly superior.1 –3 Nonetheless, many patients switch MAbs owing to insufficient response or adverse effects, or to treat comorbidities. Switching MAbs often improves asthma, yet the frequency, causality, and outcome of switches remain understudied.4–6 Thus, universal, standardized responder criteria are needed. “Biologics Asthma Response Score” (BARS) combines asthma control test, daily oral corticosteroid dose, and annualized exacerbation rate, using a s...
Source: Annals of Allergy, Asthma and Immunology - August 12, 2023 Category: Allergy & Immunology Authors: Moritz Z. Kayser, Ben L. J ülicher, Tobias Welte, Jan Fuge, Hendrik Suhling Tags: Letters Source Type: research
Real-world Severe Asthma Biologic Administration and Adherence Differs by Biologic: CHRONICLE Study Results
CONCLUSION: Patients with SA are mostly adherent to biologic therapies. Biologics with shorter dosing intervals and at-home administration had worse adherence, likely due to greater opportunities for delays. Specialist-reported administration data provide a unique perspective on biologic adherence, which may be overestimated for at-home administrations by insurance claims data.PMID:37506846 | DOI:10.1016/j.anai.2023.07.017
Source: Annals of Allergy, Asthma and Immunology - July 28, 2023 Category: Allergy & Immunology Authors: Dennis K Ledford Weily Soong Warner Carr Jennifer Trevor Laren Tan Donna Carstens Christopher S Ambrose Source Type: research
Marginal Zone
Cartootorial: Food-allergic patients often experience anxiety about the possibility of a life-threatening reaction from an accidental exposure.1 While FDA-approved therapies to prevent this remain limited, anti-IgE biologics have shown promise for this indication.1,2,3 As monotherapy, omalizumab and a similar drug, TNX-901, significantly increased the reaction threshold in peanut-allergic patients from
Source: Annals of Allergy, Asthma and Immunology - June 30, 2023 Category: Allergy & Immunology Authors: Erin L. Reigh Tags: Marginal Zone Source Type: research
Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial
Source: Journal of Asthma and Allergy - June 24, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Updates in the Role of Biologics in Asthma
AbstractPurpose of ReviewThe purpose of this review is to provide an update on the current biologic treatments available for severe asthma, focusing on the mechanism and clinical efficacy of each agent. Prior to the FDA approval for biologic agents, patients diagnosed with severe asthma frequently depended on the use of systemic steroids in order to control their disease. Since the introduction of first approved biologic for IgE-mediated asthma, other biologic agents surfaced and are now available for other asthma phenotypes.Recent FindingsIn addition to omalizumab, which targets IgE-mediated asthma, there are now multiple...
Source: Current Treatment Options in Allergy - June 20, 2023 Category: Allergy & Immunology Source Type: research
Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
Source: Journal of Asthma and Allergy - June 19, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Efficacy of Second-Line Treatments in Chronic Urticaria Refractory to Standard Dose Antihistamines
CONCLUSIONS: In patients with CU refractory to standard doses of nsAHs, both updosing of nsAHs 4-fold and multiple combination treatment with 4 nsAHs increased the rate of well-controlled cases without causing significant adverse effects. Updosing of nsAHs is more effective for complete CU control than combination treatment.PMID:37153977
Source: Allergy, Asthma and Immunology Research - May 8, 2023 Category: Allergy & Immunology Authors: Mi-Ae Kim Jeong-Hee Choi Yoo-Seob Shin Hae-Sim Park Young-Min Ye KAAACI Work Group on Urticaria/Angioedema/Anaphylaxis Source Type: research
